Media Contact:
Lorraine Marshall Wright
lmwright@holaira.com

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD

Minneapolis, Minn., June 27, 2017 – Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of Targeted Lung Denervation* (TLD) using the Nuvaira™ Lung Denervation System in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The AIRFLOW-2 (NCT#02058459) trial, designed to assess the safety of TLD in patients suffering from moderate to severe COPD at 16 institutions throughout Western Europe, included 82 patients. COPD is one of the leading causes of morbidity and mortality worldwide. It is […]

Holaira Announces Company Name Change to Nuvaira

Company Adds Shane Gleason to Executive Team  Minneapolis, Minn., June 20, 2017 – Holaira, a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to Nuvaira, effective immediately. In addition, the company unveiled a new corporate identity and website, available at www.nuvaira.com. The company also announced the addition of Shane Gleason as chief commercial officer. Shane is an accomplished industry executive with 18 years of healthcare sales and operations experience, most recently as the vice president of sales for North America at Cordis, a Cardinal Health company. “We are proud to launch […]

Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in Obstructive Lung Disease at ERS

London, Sept. 5, 2016Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, announced it will host an educational symposium on the use of Targeted Lung Denervation* (TLD) in obstructive lung disease during the European Respiratory Society International Congress, Sept. 6, in London.

First COPD Patient Treated in Holaira’s Sham Controlled Trial of Targeted Lung Denervation

Minneapolis, Minn., Aug. 3, 2016 – Holaira, a developer of medical devices to treat obstructive lung diseases, announced the initiation of treatments in the AIRFLOW-2 Clinical Trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD) in a procedure called Targeted Lung Denervation* (TLD). Under the direction of principal investigator, Christophe Pison, M.D., Ph.D., the first patient was treated at the Grenoble University Hospital Centre (CHUG) in Grenoble, France, using the Holaira™ Lung Denervation System.

"We are encouraged by our experience in the AIRFLOW-2 trial using the Nuvaira System. Because COPD is a progressive disease that affects millions of people and places a significant financial burden on the system, it is imperative that we find better methods of treatment. This new COPD technology may offer a true breakthrough for patients by providing long-term clinical improvement from a one-time procedure."

Felix Herth, M.D., Ph.D, FCCP